Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| TriSalus Life Sciences, Inc.TLSI · Entity 5872 | Director | May 15, 2026 | May 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
TriSalus Life Sciences, Inc.
Report date May 15, 2026 · Filed May 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,240,722 |
Reported balance
After 2026-05-15 transaction · row 1
1 source rowRow 1 · 2026-05-15 · Purchase · Acquired 410,000 · Balance 1,240,722 F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.47 to $2.55 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. |
| Common StockSEC Table I · non-derivative | IndirectBy Skyview Investments LLC | 399,698 |
Reported balance
After 2026-05-15 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-05-15 · Purchase · Acquired 200,000 · Balance 399,698 F2: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.46 to $2.52 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F3: The securities reported herein are owned by Skyview Investments LLC. Mr. Stansky serves as managing member of Skyview Investments LLC (and in such capacity may be deemed to beneficially own the securities reported herein). Voting and dispositive power over the securities owned by Skyview Investments LLC is exercised in his capacity as managing member. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.47 to $2.55 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
F2: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.46 to $2.52 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
F3: The securities reported herein are owned by Skyview Investments LLC. Mr. Stansky serves as managing member of Skyview Investments LLC (and in such capacity may be deemed to beneficially own the securities reported herein). Voting and dispositive power over the securities owned by Skyview Investments LLC is exercised in his capacity as managing member.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 15, 2026 Filed May 18, 2026 16:42 UTC | TriSalus Life Sciences, Inc. TLSI · Entity 5872 | PurchaseCommon Stock | 200,000 | $2.50 | $500,000.00 |
DisclosureSEC source: 0001628280-26-035995 · wk-form4_1779136952.xml · nonDerivative · entry 2 Stansky Michael P · CIK 0001424204 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Skyview Investments LLC Disclosed balance after: 399,698 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.46 to $2.52 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F3 · ownership.nature: The securities reported herein are owned by Skyview Investments LLC. Mr. Stansky serves as managing member of Skyview Investments LLC (and in such capacity may be deemed to beneficially own the securities reported herein). Voting and dispositive power over the securities owned by Skyview Investments LLC is exercised in his capacity as managing member. Read SEC document |
| May 15, 2026 Filed May 18, 2026 16:42 UTC | TriSalus Life Sciences, Inc. TLSI · Entity 5872 | PurchaseCommon Stock | 410,000 | $2.50 | $1,025,000.00 |
DisclosureSEC source: 0001628280-26-035995 · wk-form4_1779136952.xml · nonDerivative · entry 1 Stansky Michael P · CIK 0001424204 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,240,722 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.47 to $2.55 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document |
| May 14, 2026 Filed May 15, 2026 20:39 UTC | TriSalus Life Sciences, Inc. TLSI · Entity 5872 | GrantDirector Stock Option (right to buy) · Derivative | 47,003 | $0.00 Strike: $2.52 | $0.00 |
DisclosureSEC source: 0001628280-26-035662 · wk-form4_1778877538.xml · derivative · entry 4 Stansky Michael P · CIK 0001424204 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 139,540 Underlying: Common Stock · 47,003 shares Expires 2036-05-13 F4 · derivative.exercise_date: The shares subject to the option shall fully vest on the one-year anniversary of the grant date of May 14, 2026, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| May 14, 2026 Filed May 15, 2026 20:39 UTC | TriSalus Life Sciences, Inc. TLSI · Entity 5872 | GrantCommon Stock | 20,089 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-035662 · wk-form4_1778877538.xml · nonDerivative · entry 2 Stansky Michael P · CIK 0001424204 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 830,722 F2 · shares: Represents grant of restricted stock units (the "Retainer RSU Award") payable solely in common stock of the Issuer. The Reporting Person elected to receive the Retainer RSU Award in lieu of 2026 board service retainer cash fees provided for under the Issuer's Non-Employee Director Compensation Policy. The shares subject to the Retainer RSU Award shall vest quarterly in equal one-third installments through the remainder of 2026, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| May 14, 2026 Filed May 15, 2026 20:39 UTC | TriSalus Life Sciences, Inc. TLSI · Entity 5872 | GrantCommon Stock | 23,501 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-035662 · wk-form4_1778877538.xml · nonDerivative · entry 1 Stansky Michael P · CIK 0001424204 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 810,633 F1 · shares: Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. The shares subject to the RSU award shall fully vest on the one-year anniversary of the grant date of May 14, 2026, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| February 23, 2026 Filed Feb 23, 2026 21:08 UTC | TriSalus Life Sciences, Inc. TLSI · Entity 5872 | PurchaseCommon Stock | 117,198 | $4.10 | $480,511.80 |
DisclosureSEC source: 0001628280-26-010602 · wk-form4_1771880877.xml · nonDerivative · entry 2 Stansky Michael P · CIK 0001424204 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By LLC Disclosed balance after: 199,698 F1 · ownership.nature: These securities were purchased by Skyview Investments LLC. Mr. Stansky serves as managing member of Skyview Investments LLC (and in such capacity may be deemed to beneficially own the securities reported herein). Voting and dispositive power over the securities owned by Skyview Investments LLC is exercised in his capacity as managing member. Read SEC document |
| February 23, 2026 Filed Feb 23, 2026 21:08 UTC | TriSalus Life Sciences, Inc. TLSI · Entity 5872 | PurchaseCommon Stock | 243,900 | $4.10 | $999,990.00 |
DisclosureSEC source: 0001628280-26-010602 · wk-form4_1771880877.xml · nonDerivative · entry 1 Stansky Michael P · CIK 0001424204 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 787,132 Read SEC document |
| February 04, 2026 Filed Feb 11, 2026 23:51 UTC | TriSalus Life Sciences, Inc. TLSI · Entity 5872 | GrantDirector Stock Option (right to buy) · Derivative | 92,537 | $0.00 Strike: $4.91 | $0.00 |
DisclosureSEC source: 0001628280-26-007409 · wk-form4_1770853869.xml · derivative · entry 1 Stansky Michael P · CIK 0001424204 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,537 Underlying: Common Stock · 92,537 shares Expires 2036-02-03 F1 · derivative.exercise_date: The shares subject to this stock option vest in three equal annual installments commencing on February 4, 2027, subject to the Reporting Person's continued service with the Issuer on each respective vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.